The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 24191305)

Published in Eur J Prev Cardiol on November 04, 2013

Authors

Hiddo J Lambers Heerspink1, Peggy Gao, Dick de Zeeuw, Catherine Clase, Gilles R Dagenais, Peter Sleight, Eva Lonn, Koon T Teo, Salim Yusuf, Johannes F Mann

Author Affiliations

1: Department of Clinical Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Associated clinical trials:

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. | NCT00153101

Articles by these authors

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76

2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet (2011) 13.10

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72

Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med (2009) 11.49

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25

Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. Eur Heart J (2006) 10.77

Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet (2004) 9.01

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr (2008) 7.91

Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83

Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54

Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35

Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25

Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08

Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81

Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA (2005) 6.68

Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med (2010) 6.48

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38

Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int (2004) 6.32

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet (2010) 6.31

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16

Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol (2013) 5.97

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol (2009) 5.65

Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med (2003) 5.47

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47

Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25

Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24

Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 5.19

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 4.99

Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91

Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86

Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83

Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68

Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58

Defining obesity cut points in a multiethnic population. Circulation (2007) 4.42

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol (2005) 4.40

Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet (2008) 4.37

Need for expertise based randomised controlled trials. BMJ (2005) 4.34

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33

Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med (2012) 4.32

Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. N Engl J Med (2013) 4.27

Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. Circulation (2005) 4.21

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int (2011) 3.96

Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91

Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81

The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res (2006) 3.80

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet (2015) 3.79

Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med (2007) 3.74

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71

Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67

Validation and comparison of three formulae to estimate sodium and potassium excretion from a single morning fasting urine compared to 24-h measures in 11 countries. J Hypertens (2014) 3.66

Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J (2008) 3.64